Cormorant Asset Management’s IGM Biosciences IGMS Stock Holding History

Cormorant Asset Management’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-402,200	Closed	-$10.8M	–	83
2022 Q1	$10.8M	Sell	402,200 -97,800	-20%	-$1.82M	0.83%	36
2021 Q4	$14.7M	Buy	500,000 +150,000	+43%	+$7.45M	0.87%	33
2021 Q3	$23M	Buy	350,000 +100,000	+40%	+$7.65M	0.94%	32
2021 Q2	$20.8M	Sell	250,000 -245,769	-50%	-$18.2M	0.71%	40
2021 Q1	$38M	Sell	495,769 -104,231	-17%	-$9.49M	0.85%	29
2020 Q4	$53M	Buy	600,000 +375,000	+167%	+$26.4M	1.26%	29
2020 Q3	$16.6M	Sell	225,000 -115,146	-34%	-$6.82M	0.64%	42
2020 Q2	$24.8M	Sell	340,146 -85,958	-20%	-$5.22M	0.95%	34
2020 Q1	$23.9M	Buy	426,104 +269,704	+172%	+$11.8M	1.11%	30
2019 Q4	$5.97M	Hold	156,400	–	–	0.24%	57
2019 Q3	$2.78M	Buy	+156,400	New	+$3.16M	0.17%	64

Other funds holding IGMS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cormorant Asset Management's IGMS Position: Q2 2022 in Review

Cormorant Asset Management sold out of IGM Biosciences (IGMS) in Q2 2022, closing a stake of 402,200 shares — an estimated $10.8M sold.

Cormorant Asset Management first reported a position in IGMS in Q3 2019 and held it in 11 quarters. The position peaked at $53M in Q4 2020. 89 funds tracked by Wall St. Rank hold IGMS as of Q2 2022.

Cormorant Asset Management reported no remaining IGM Biosciences position as of Q2 2022 after selling out during the quarter.
Cormorant Asset Management sold 402,200 IGM Biosciences shares in Q2 2022, an estimated $10.8M.
Cormorant Asset Management first reported a position in IGM Biosciences in Q3 2019 and held it in 11 quarters.
Cormorant Asset Management's IGM Biosciences position peaked at $53M in Q4 2020.
89 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2022.

Based on Cormorant Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.